E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Metastatic castration-resistant prostate carcinoma men, aged >/= 18 years |
|
E.1.1.1 | Medical condition in easily understood language |
Metastatic castration-resistant prostate cancer |
Cancer de la prostate présentant des localisations secondaires (métastases) et maladie évoluant malgré une privation hormonale appelée castration |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10036909 |
E.1.2 | Term | Prostate cancer metastatic |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Non-progression rate at 12 weeks in patients receiving ABI at a dose of 2000 mg / day after failure of standard dose (1000 mg/day). |
|
E.2.2 | Secondary objectives of the trial |
Step 1: - Incidence of underexposure to ABI during the first three months in patients treated at standard dose (1000 mg/day) and identification of inter- and intra-individual variability factors of plasma levels of ABI. - Evaluation of medical adherence and correlation with mean ABI concentration and socioeconomic conditions. - Progression free survival (time from the day of inclusion to disease progression or death) and correlation with underexposure to ABI. Step 2: - PSA response rate. - Progression free survival. - Safety of ABI at a dose of 2000 mg/day. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Step 1 - Male 18 years and older. - Voluntary signed informed consents of the patient - Histologically confirmed prostate adenocarcinoma. - Presence of bone and/or soft-tissue and/or visceral metastases through CT scan, MRI, or scintigraphy scan. - Progressive disease assessed by PSA, CT scan, MRI or bone scan according to the PCGW3 criteria - Patient with no or moderate symptoms (no need for continuous opioid treatment) - Effective castration confirmed by testosterone plasma level < 50 ng/mL - ECOG performance status: 0-2 - Life expectancy > 3 months - Patient affiliate to french social secutity - Laboratory criteria: SGPT and SGOT < 5 fold the upper normal value Kaliemia > 3 mM Step 2 - Patients receiving ABI 1000 mg/day through step 1 for at least two months - At least two measures of ABI plasma concentrations available within the first three months of treatment - Mean of ABI concentration < 8,5ng/mL. - Progressive disease according to PCWG3 criteria within 28 weeks following starting of ABI in the step 1 (according to PCWG3 criteria of progression at trial entry, isolated PSA increase will be accepted). - Inclusion in step 2 must occur within 2 months following the first observation of cancer progression while in step 1. |
|
E.4 | Principal exclusion criteria |
Step 1 - Pure small cell carcinoma of the prostate or predominant histology of neuro-endocrine carcinoma - Confirmed brain and/or leptomeningeal metastases - Previous treatment with docetaxel or any other anticancer treatment for castration-resistant prostate carcinoma (previous docetaxel for hormone-sensitive metastatic disease is allowed) - Previous treatment with ABI or any other 17 B hydroxylase inhibitor or Enzalutamide -Treatment with first-generation antiandrogen performed on the day of screening or within previous four weeks. - Patient co-morbidities: Galactose hypersensitivity, Lapp lactase deficiency. Cirrhosis Child-Pugh B or C Active or symptomatic viral hepatitis Heart failure stage NYHA III or IV Cardiac arythmia, heart failure stage NYHA II, ischemic cardiopathy or uncontroled hypertension, except if left ventricular ejection fraction is > 50% Patients with left ventricular ejection fraction (LVEF) < 50% Severe hypokaliema
Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment related complications. Prior or concurrent malignant disease in complete remission for less than 3 years, except T1N0 vocal cord carcinoma, basal or squamous cell skin carcinoma and in situ transitional cell bladder carcinoma - Limitation of the patient's ability to comply with the treatment or to follow the protocol. Step 2 - Persistent grade 3-4 toxicities related to ABI. In case of persistent grade 2 toxicity or resolutive grade 3-4 toxicities, inclusion in step 2 must be discussed in a case by case basis with the study coordinating Investigator. - All non-inclusion criteria for step 1 apply - Patient who does not take ABI daily at the investigator opinion |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the proportion of patients who do not experience progressive disease at 12 weeks from the day of inclusion in step 2. At 12 weeks, disease progression will be defined by PSA and/or radiographic progression.
Secondary endpoints are : - Underexposure to ABI - Measure of medical adherence - PSA response rate - Progression-free survival - Safety of dose escalation |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Underexposure to ABI Measure of medical adherence PSA response rate Progression-free survival Safety of dose escalation |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
non-comparatif |
non-comparative phase 2 study |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |